New wrinkle treatment shows promise in asian trial
NCT ID NCT06308198
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 study tested an investigational botulinum toxin injection called AGN-151586 against a placebo for treating moderate to severe frown lines (glabellar lines). About 160 adults in China, Taiwan, and Japan received either the active injection or a placebo into five points between the eyebrows. The study measured how well the treatment reduced wrinkle severity and monitored side effects. Results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGN-151586 (botulinum toxin type A injection)
What this could lead to
If it works, this could offer a new option for temporarily reducing frown lines between the eyebrows.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. As with any injection, side effects like bruising, pain, or temporary muscle weakness are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLABELLAR LINES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital /ID# 256084
Beijing, Beijing Municipality, 100730, China
-
Dermatology Hospital of Southern Medical University /ID# 256172
Guangzhou, Guangdong, 510091, China
-
Huashan Hospital, Fudan University /ID# 255870
Shanghai, Shanghai Municipality, 200040, China
-
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 260669
Kaohsiung City, 807, Taiwan
-
Nanjing Drum Tower Hospital /ID# 255936
Nanjing, Jiangsu, 210008, China
-
Tokyo Center Clinic /ID# 267380
Chuo-ku, Tokyo, 103-0027, Japan
-
Tri-Service General Hospital /ID# 260673
Taipei, 11490, Taiwan
-
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 255871
Wuhan, Hubei, 430022, China
-
Wuxi People's Hospital /ID# 256029
Wuxi, Jiangsu, 214023, China
-
Xianyang Hospital of Yan'an University /ID# 256774
Xianyang, Shaanxi, 712000, China
-
Zhejiang Provincial People's Hospital /ID# 256028
Hangzhou, Zhejiang, 310014, China
-
Zhongda Hospital Southeast University /ID# 255937
Nanjing, Jiangsu, 210009, China